Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders
Alzheimer's Disease
- 2nd Edition - November 1, 2025
- Latest edition
- Editor: Adeboye Adejare
- Language: English
Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer’s Disease, Second Edition delves into the complexities of drug discovery, specifically… Read more
Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer’s Disease, Second Edition delves into the complexities of drug discovery, specifically for Alzheimer's Disease, presenting the necessary paradigm for future success in research and treatment. This edition is thoroughly updated with recent developments in therapeutic strategies, including amyloid hypothesis, tau, apo E, insulin, and others, and introduces a new chapter on drug delivery to the brain. Additionally, the book encompasses diagnosis, epidemiology, drug discovery strategies, current therapeutics, and more, offering a comprehensive approach to Alzheimer's Disease.
It covers the latest in targeted drug design, preclinical studies, and animal models, making it an essential resource for pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers. Patients and advocacy groups can also gain valuable insights from the overview of current treatments and scientific advancements in the field.
It covers the latest in targeted drug design, preclinical studies, and animal models, making it an essential resource for pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers. Patients and advocacy groups can also gain valuable insights from the overview of current treatments and scientific advancements in the field.
- Covers Monoclonal Antibodies approaches
- Provides a compilation of chemical considerations required in drug discovery for the treatment of neurodegenerative disorders
- Explores how in vitro and in vivo models translate to human physiology
Professionals involved in the drug discovery process, whether in academia, research institutes or the pharmaceutical industry
1. Neurodegenerative disorders: why do we need new therapies?
2. Cognitive and functional considerations in Alzheimer’s disease diagnosis
3. National plan and resources to address Alzheimer’s disease
4. Biosensor approaches in the diagnosis of a neurodegenerative disorder
5. Current therapies for the treatment of Alzheimer’s disease: small molecules - Acetylcholine esterase inhibitors and NMDA receptor antagonist
6. Physicochemical properties for potential AD drugs
7. Receptor targets in Alzheimer’s disease drug discovery
8. Amyloid hypothesis in the development of therapeutic agents for Alzheimer’s disease 9: Tau proteins
10. Cholesterol and fat metabolism in Alzheimer’s disease
11. Mitochondria as a therapeutic target for the treatment of Alzheimer’s disease
12. Peptide-based therapeutics
13. Anti-inflammatory and immunomodulating agents
14. Prion and other protein folding hypotheses
15. Simple in vivo models of Alzheimer’s disease
16. Rodent models for Alzheimer’s disease drug discovery
17. Drug delivery to the brain
18. Alzheimer’s disease drugs in clinical trials
19. Biologics for the treatment of Alzheimer’s disease
20. Brain health
21. Non-pharmacologic treatment approaches
2. Cognitive and functional considerations in Alzheimer’s disease diagnosis
3. National plan and resources to address Alzheimer’s disease
4. Biosensor approaches in the diagnosis of a neurodegenerative disorder
5. Current therapies for the treatment of Alzheimer’s disease: small molecules - Acetylcholine esterase inhibitors and NMDA receptor antagonist
6. Physicochemical properties for potential AD drugs
7. Receptor targets in Alzheimer’s disease drug discovery
8. Amyloid hypothesis in the development of therapeutic agents for Alzheimer’s disease 9: Tau proteins
10. Cholesterol and fat metabolism in Alzheimer’s disease
11. Mitochondria as a therapeutic target for the treatment of Alzheimer’s disease
12. Peptide-based therapeutics
13. Anti-inflammatory and immunomodulating agents
14. Prion and other protein folding hypotheses
15. Simple in vivo models of Alzheimer’s disease
16. Rodent models for Alzheimer’s disease drug discovery
17. Drug delivery to the brain
18. Alzheimer’s disease drugs in clinical trials
19. Biologics for the treatment of Alzheimer’s disease
20. Brain health
21. Non-pharmacologic treatment approaches
- Edition: 2
- Latest edition
- Published: November 1, 2025
- Language: English
AA
Adeboye Adejare
Adeboye Adejare’s research group is interested in the areas of design and syntheses of small organic molecules to probe neurodegeneration, especially Alzheimer’s disease, and for treatment of cancer. They are also interested in in vitro models of drug absorption and ability to cross blood brain barrier; drug targeting; pharmaceutical profiling; and chemistry of fluoroaromatic compounds. The research is funded by the National Institutes of Health, the Office of Naval Research, and several pharmaceutical companies. These efforts have resulted in over 50 publications, 5 patents, and over 100 presentations at meetings, including invited presentations at national and international conferences. He also serves on several national panels, including those by NIH, NSF, and Alzheimer’s Association.
Dr. Adejare is the editor of Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer’s Disease which is also published by Elsevier.
Affiliations and expertise
Professor, Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA